Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Early treatment response in alcohol dependence with extended-release naltrexone.

Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM.

J Clin Psychiatry. 2008 Feb;69(2):190-5.

PMID:
18348601
2.

The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.

Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA.

J Clin Psychopharmacol. 2006 Dec;26(6):610-25. Review.

PMID:
17110818
3.
4.

Opioid antagonists for alcohol dependence.

Srisurapanont M, Jarusuraisin N.

Cochrane Database Syst Rev. 2000;(3):CD001867. Review. Update in: Cochrane Database Syst Rev. 2002;(2):CD001867.

PMID:
10908513
5.

Long-acting injectable naltrexone for the treatment of alcohol dependence.

Mannelli P, Peindl K, Masand PS, Patkar AA.

Expert Rev Neurother. 2007 Oct;7(10):1265-77. Review.

PMID:
17939765
6.

Intramuscular extended-release naltrexone: current evidence.

Gastfriend DR.

Ann N Y Acad Sci. 2011 Jan;1216:144-66. doi: 10.1111/j.1749-6632.2010.05900.x. Review. Erratum in: Ann N Y Acad Sci. 2011 Apr;1224(1):207. Ann N Y Acad Sci. 2011 Apr;1224(1):207.

PMID:
21272018
8.

Extended-release intramuscular naltrexone.

Swainston Harrison T, Plosker GL, Keam SJ.

Drugs. 2006;66(13):1741-51. Review.

PMID:
16978037
9.

A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder.

Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, Ball S, Russell J.

J Psychopharmacol. 2008 Jun;22(4):417-25. doi: 10.1177/0269881108091588.

PMID:
18635722
10.

Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.

Goonoo N, Bhaw-Luximon A, Ujoodha R, Jhugroo A, Hulse GK, Jhurry D.

J Control Release. 2014 Jun 10;183:154-66. doi: 10.1016/j.jconrel.2014.03.046. Epub 2014 Apr 2. Review.

PMID:
24704710
11.

A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence.

Roozen HG, de Waart R, van der Windt DA, van den Brink W, de Jong CA, Kerkhof AJ.

Eur Neuropsychopharmacol. 2006 Jul;16(5):311-23. Epub 2005 Dec 19. Review.

PMID:
16361086
12.

Dosing issues in the pharmacotherapy of alcoholism.

Mason BJ.

Alcohol Clin Exp Res. 1996 Oct;20(7 Suppl):10A-16A. Review.

PMID:
8904989
14.

[Alcohol dependence and mental adaptation disorders (the use of injectable extended-release naltrexone)].

Agibalova TV, Rychkova OV, Kuznetsov AG, Gurevich GL, Val'chuk DS, Petrov AD.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(6 Pt 2):63-8. Review. Russian.

PMID:
23887471
15.
16.

Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review.

Swift R, Oslin DW, Alexander M, Forman R.

J Stud Alcohol Drugs. 2011 Nov;72(6):1012-8. Review.

PMID:
22051215
17.

Naltrexone: Not Just for Opioids Anymore.

Sudakin D.

J Med Toxicol. 2016 Mar;12(1):71-5. doi: 10.1007/s13181-015-0512-x. Review.

18.

Reduction in heavy drinking as a treatment outcome in alcohol dependence.

Gastfriend DR, Garbutt JC, Pettinati HM, Forman RF.

J Subst Abuse Treat. 2007 Jul;33(1):71-80. Epub 2007 Feb 22. Review.

PMID:
17588491
19.

Vivitrex (Alkermes/Cephalon).

Heading CE.

Curr Opin Investig Drugs. 2006 Jan;7(1):81-8. Review.

PMID:
16425675
20.

Extended-release intramuscular naltrexone in alcohol dependence in adults: profile report.

Swainston Harrison T, Plosker GL, Keam SJ.

CNS Drugs. 2007;21(1):83-7. Review. No abstract available.

PMID:
17190531

Supplemental Content

Support Center